Amazon Pharmacy offers real-time medication availability, transparent pricing starting as low as $1 per day with insurance and $5 per day for cash pay with automatic manufacturer-sponsored coupons, soon available via in-office kiosks within minutes.
Oral GLP-1 therapy achieves double-digit weight loss in trials and launches this month with no food or water restrictions, expanding access through retail and direct-to-consumer channels.
鈥淥ur customers and communities want affordable, effective weight-management treatment options with real affordability,鈥� said Colleen Lindholz, group vice president and president of Kroger Health.
The success of Eli Lilly鈥檚 Zepbound is encouraging efforts to expand access to obesity treatments by clarifying pricing and reducing costs.
Used by millions of patients worldwide, the KwikPen for single-patient use offers a new option for receiving Zepbound.
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide.
Strive Compounding Pharmacy accuses drugmakers of anti-competitive actions to suppress lawful compounded GLP-1 medications and restrict patient choice.
The drugmaker鈥檚 GLP-1 portfolio achieved triple-digit sales growth in Q3, strengthening Lilly鈥檚 leadership in the growing weight-loss market.
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
The enhanced facility will be among those that will manufacture for orforglipron, Lilly鈥檚 first oral, small-molecule GLP-1 receptor agonist.
Eli Lilly announced its Team USA lineup for the 2026 Winter Games. The company will also expand its Milestones into Meaning program.
鈥淢oderate-to-severe obstructive sleep apnea is more than just snoring 鈥� it鈥檚 a serious condition and it deserves serious attention,鈥� O鈥橬eal said.
The acquisition strengthens Lilly鈥檚 genetic medicine pipeline and expands its footprint in ophthalmology.
Lilly鈥檚 oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
Eli Lilly and Company enhances digital healthcare offerings to address delays in diagnosis and treatment.
